We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

This study is currently recruiting participants.
Verified August 29, 2017 by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )
Sponsor:
ClinicalTrials.gov Identifier:
NCT00339885
First Posted: June 21, 2006
Last Update Posted: October 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )
June 19, 2006
June 21, 2006
October 6, 2017
March 24, 1995
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00339885 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

The aim of the project is to positionally clone susceptibility genes for NIDDM. Patients will be ascertained in Finland from previous health surveys and hospital discharge records. Approximately 400 affected sib pairs will be collected. Families will be chosen who have, at most, one parent with NIDDM no history of IDDM. A clinical examination will be undertaken on family members and blood drawn for DNA isolation. Covariates such as body weight, blood pressure, lipid levels and urinary albumin will also be measured. The unaffected spouse and children of a subset of probands will be invited to undergo a frequently-sampled intravenous glucose tolerance test (FSIGT) to measure parameters of pancreatic function and peripheral insulin resistance (IR). A number of unrelated elderly non-diabetic subjects will also be identified to conduct a population-based association analysis.

The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda where a total genomic scan will be performed using semi-automated fluorescence-based genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann Arbor where parametric and non-parametric methods will be used to analyse both discrete traits such as NIDDM and intermediate traits like IR.

The Finland-United States investigation of NIDDM (FUSION) study is a long-term effort to

identify susceptibility genes for Type 2 diabetes (T2D) and associated quantitative traits. This

involves the phenotyping and DNA analysis of thousands of individuals living in Finland, utilizing a study design that was originally based on affected sib pairs. The majority of these samples have already been subjected to a genome scan using microsatellite markers and the original FUSION samples. Additionally, thousands of other northern European cases and controls have been subjected to genome-wide association (GWA) analysis and/or fine mapping as part of the FUSION study. More recently, the opportunity provided by the lowered sequencing costs have allowed targeted and/or whole genome sequencing of many of these individuals.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Non-Insulin Dependent Diabetes Mellitus
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60000
Not Provided
Not Provided
  • No eligibility criteria listed.
Sexes Eligible for Study: All
12 Months and older   (Child, Adult, Senior)
Yes
Contact: Ann C. M. Smith (301) 435-5475 acmsmith@nhgri.nih.gov
Contact: Lori Bonnycastle, Ph.D. (301) 594-9206 lbonnyca@mail.nih.gov
Finland,   Germany,   Norway
United States
 
NCT00339885
999995030
OH95-HG-N030
Not Provided
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )
National Human Genome Research Institute (NHGRI)
Not Provided
Principal Investigator: Lori Bonnycastle, Ph.D. National Human Genome Research Institute (NHGRI)
National Institutes of Health Clinical Center (CC)
August 29, 2017